Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Sandler

Showing results (61-70 of 90) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancerVincent A Miller, David H Johnson, Lee M Krug, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2009
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimenStuart Salmon, Heidi Chen, Shuo Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerRoy S Herbst, Diane Prager, Robert Hermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer modelsJeffrey M Albert, Carolyn Cao, Kwang Woon Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility CriteriaPhilip Bonomi, Gideon Blumenthal, Andrea Stern Ferris, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 15, 2007
Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancerJeffrey M Albert, Adriana Gonzalez, Pierre P Massion, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungsGregory A Otterson, Miguel A Villalona-Calero, Sunil Sharma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLCDavid R Spigel, Jamie E Chaft, Scott Gettinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancerChristopher J Sweeney, Chris H Takimoto, Jane E Latz, et al.
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Pageof 9

Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancerVincent A Miller, David H Johnson, Lee M Krug, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2009
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimenStuart Salmon, Heidi Chen, Shuo Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerRoy S Herbst, Diane Prager, Robert Hermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer modelsJeffrey M Albert, Carolyn Cao, Kwang Woon Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility CriteriaPhilip Bonomi, Gideon Blumenthal, Andrea Stern Ferris, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 15, 2007
Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancerJeffrey M Albert, Adriana Gonzalez, Pierre P Massion, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungsGregory A Otterson, Miguel A Villalona-Calero, Sunil Sharma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLCDavid R Spigel, Jamie E Chaft, Scott Gettinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancerChristopher J Sweeney, Chris H Takimoto, Jane E Latz, et al.
Lancet (London, England)|March 14, 2016
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialLouis Fehrenbacher, Alexander Spira, Marcus Ballinger, et al.
Pageof 9